<DOC>
	<DOCNO>NCT01622283</DOCNO>
	<brief_summary>This study single center , open-label , randomize , single dose , fasted condition 2-way crossover study evaluate pharmacokinetics , safety tolerability levocetirizine oral solution 5 mg cetirizine dry syrup 10 mg Japanese healthy male subject . Approximately 20 subject receive treatment levocetirizine oral solution 5 mg cetirizine dry syrup 10 mg design . Serial pharmacokinetic sample collect safety assessment perform follow dose . The primary objective study demonstrate bioequivalence levocetirizine plasma , give levocetirizine oral solution 5 mg relative cetirizine DS 10 mg Japanese healthy male subject .</brief_summary>
	<brief_title>Pharmacokinetic Study Levocetirizine Oral Solution</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Levocetirizine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Japanese male 20 55 year age inclusive , time signing informed consent . Nonsmoker exsmoker cease smoke least 6 month . Body weight = &gt; 50 kg BMI within range 18.5 25.0 kg/m2 screening . A signed date write informed consent obtain subject . Able complete study procedure plan treatment period . ALT , alkaline phosphatase bilirubin = &lt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Single QTcB &lt; 450 msec screening . The subject positive syphilis , Hepatitis B surface antigen , Hepatitis C antibody , HIV1/2 antibody , HTLV1 antibody screen . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . The subject history allergic rhinitis . The subject currently participate another clinical study postmarketing study subject expose investigational noninvestigational drug device . The subject history current condition drug abuse alcoholism . A positive prestudy drug screen . History regular alcohol consumption within 6 month study define average weekly intake &gt; 14 drink . One drink equivalent 12 g alcohol : 12 ounce ( 350 mL ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . The subject participate clinical trial receive investigational product noninvestigational drug within 4 month prior first dose day current study . Exposure four new chemical entity within 12 month prior first dose day . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 14 day 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy . Where participation study would result donation blood blood product = &gt; 400 mL within 3 month = &gt; 200 mL within 1 month . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>